Here are four takeaways:
1. The analysts have a price target of $23 on K2M shares.
2. On Oct. 7, K2M shares rallied 1.38 percent, hitting $18.40.
3. Since March 7, 2016, the shares have increased 38.35 percent and are uptrending.
4. K2M shares have outperformed the S&P 500 by 30.75 percent.
More device news:
St. Jude Medical receives FDA approval, announces 1st implant of Infinity DBS system: 5 observations
Zacks downgrades Entellus Medical to ‘hold’: 4 thoughts
NIH awards RIVANNA $1.5M grant to develop anesthesia platform for orthopedic care: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
